In the aftermath of the cyberattack against US hospital group HCA, HBI talks to two cybersecurity providers to find out how worried operators, investors and patients should be.
Germany-based healthcare conglomerate Fresenius’ restructuring plans seem to be gathering steam, as HBI hears the sale of its Spain-based fertility clinic Eugin is imminent.
Telehealth company Babylon will be merged with digital neurotherapy company MindMaze and taken private by its creditors. HBI catches up with two digital health experts to discuss what happened to Babylon and what the sorry saga means for the market.
In the US, firms like Amazon have been looking to dominate the patient journey, a move which seems unconscionable in Europe. To understand this culture shock, HBI spoke to a US-based university hospital operator.
US-based healthcare real estate investment company Flagler Healthcare Investments is eyeing up opportunities in the big five European markets. Undeterred by high levels of regulation and hyper fragmentation, the German market is of particular interest.
GenesisCare, the radiotherapy group with operations in the US, UK, Australia and Spain, has filed for voluntary reorganisation under chapter 11 of the US bankruptcy code and will look to sell off its US assets. HBI speaks to an advisory source to find out more.
As an aging population compounds Germany’s workforce crisis, the search for staff continues to expand outside Europe. With the government launching an initiative to attract skilled care workers from Brazil and beyond, HBI speaks to two market experts to find out more.
In a report published this week by the UN agency, the WHO has raised concerns about the patient safety and potential risks associated with the use of AI language platforms simulating human interactions in healthcare. Public health experts are also calling for a pause on developments until regulations have caught up.
Shareholders in Babylon, which was worth $4.2bn at listing in October 2021, face being wiped out as it reverts to private ownership as creditor Albacore takes over. CEO and founder Ali Parsa, whose remuneration totalled $7.1m in 2022, is likely to stay on, says a legal expert who says the group could face legal action.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.OkCookies Policy
